Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.51 |
| ▸ | PPARG | P37231 | 10/20 | 0.51 |
| ▸ | PPARD | Q03181 | 6/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068924 | 1.00 | PPARA (0.51) | PPARAPPARGPPARDITGB1ITGA4 | |
| SCHEMBL7069695 | 0.92 | PPARA (0.55) | PPARAPPARGPPARDCYSLTR2CYSLTR1 | |
| SCHEMBL7070013 | 0.88 | PPARA (0.67) | PPARAPPARGPPARD | |
| SCHEMBL7067698 | 0.86 | TRPV1 (0.43) | PPARAPPARGTRPV1CCKBR | |
| SCHEMBL7068926 | 0.86 | TRPV1 (0.43) | PPARAPPARGTRPV1CCKBR | |
| SCHEMBL7068771 | 0.84 | PPARG (0.55) | PPARAPPARGPPARDCYSLTR2CYSLTR1 | |
| SCHEMBL7069686 | 0.84 | PPARA (0.49) | PPARAPPARGPPARDITGB1ITGA4 | |
| SCHEMBL7069883 | 0.83 | PPARA (0.61) | PPARAPPARGPPARD | |
| SCHEMBL7069505 | 0.82 | ITGB1 (0.43) | PPARAPPARGPPARDITGB1ITGA4 | |
| SCHEMBL7069269 | 0.82 | PPARG (0.68) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | PPARA 3/4885PPARG 1/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.